Please assess the completion status of the following clinical trial:

Trial Title: Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence~* Progression after chemotherapy or appropriate TKI treatment for those patients with an EGFR-sensitizing mutation or ALK rearrangement~* KPS ≥ 70, lifespan \> 3 months, PD-L1 TPS of 1% or greater~* Platelet count ≥ 80×10\^9/L，white blood cell count ≥ 3×10\^9/L, neutrophil count ≥ 2×10\^9/L, hemoglobin ≥ 80 g/L~Exclusion Criteria:~* Patients with cardiac pacemaker~* Patients with brain metastasis~* Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction, myelosuppression, autoimmune disease, pneumonitis~* Previous treatment with a therapeutic antibody against CTLA4, PD-L1, or PD-1, or PD-L1/PD-1 pathway-targeting agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab and NK immunotherapy (Type: EXPERIMENTAL): In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
- Pembrolizumab (Type: ACTIVE_COMPARATOR): In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Based on this trial design, predict the completion outcome and termination type (if applicable).